1-((4-((4-methoxybenzyl)amino)-6-((4-(4-methylpiperazin-1-yl)benzyl)amino)-1,3,5-triazin-2-yl)amino)imidazolidine-2,4-dione | 1373917-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 1-((4-((4-methoxybenzyl)amino)-6-((4-(4-methylpiperazin-1-yl)benzyl)amino)-1,3,5-triazin-2-yl)amino)imidazolidine-2,4-dione
• 英文别名: 1-[[4-[(4-Methoxyphenyl)methylamino]-6-[[4-(4-methylpiperazin-1-yl)phenyl]methylamino]-1,3,5-triazin-2-yl]amino]imidazolidine-2,4-dione
• CAS: 1373917-57-7
• 化学式: C₂₆H₃₂N₁₀O₃
• 分子量: 532.605
• InChiKey: FEYGTSABCAWVMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• [EN] NOVEL ANTI-CANCER AGENTS<br/>[FR] NOUVEAUX AGENTS ANTICANCÉREUX
  申请人：LUDWIG INST FOR CANCER RES LTD

  公开号：WO2012054978A1

  公开（公告）日：2012-05-03

  The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.

  本发明提供了一种式（I）的化合物，或其药用可接受的衍生物、盐或前药。还提供了一种治疗患癌症的方法，包括向该患者施用有效量的式（I）的化合物，或其药用可接受的衍生物、盐或前药。此外，还提供了使用式（I）的化合物，或其药用可接受的衍生物、盐或前药制备治疗癌症药物的方法。此外，本发明还提供了一种包含式（I）的化合物，或其药用可接受的衍生物、盐或前药的药物组合物。
• Novel Anti-Cancer Agents
  申请人：Burgess Antony Wilks

  公开号：US20130261119A1

  公开（公告）日：2013-10-03

  The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or pro-drug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.

  本发明提供了式（I）的化合物或其药物可接受的衍生物、盐或前药。进一步提供了一种治疗患者癌症的方法，包括向该患者施用有效量的式（I）的化合物或其药物可接受的衍生物、盐或前药。此外，本发明还提供了使用式（I）的化合物或其药物可接受的衍生物、盐或前药制备治疗癌症的药物。此外，本发明还提供了一种包含式（I）的化合物或其药物可接受的衍生物、盐或前药的药物组合物。
• NOVEL ANTI-CANCER AGENTS
  申请人：The Walter and Eliza Hall Institute of Medical Research

  公开号：EP2632916A1

  公开（公告）日：2013-09-04
• US8835629B2
  申请人：——

  公开号：US8835629B2

  公开（公告）日：2014-09-16
• US9221799B2
  申请人：——

  公开号：US9221799B2

  公开（公告）日：2015-12-29